Bintrafusp alfa
- Generic Name
- Bintrafusp alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918149-01-5
- Unique Ingredient Identifier
- NW9K8C1JN3
- Background
Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).
- Associated Conditions
- -
- Associated Therapies
- -
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Combination therapies targeting pancreatic cancer's extracellular stroma and membrane receptors show promise. Hyaluronidase and anti-PD-L1/PD-1 antibodies enhance tumor growth inhibition. IL-6 blockade with anti-PD-L1 improves survival. VDR ligands and TGF-β inhibitors combined with checkpoint inhibitors increase T cell infiltration. CD40 agonists and CXCR4 inhibitors with anti-PD-1 show potential in enhancing anti-tumor immunity. FAK and BTK inhibitors, alongside PARP inhibitors, are being explored for their roles in improving treatment efficacy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath